Effects of serdexmethylphenidate and dexmethylphenidate: A Synthesis of Findings from 3 Studies

  1. Home
  2. Effects of serdexmethylphenidate and dexmethylphenidate
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of serdexmethylphenidate and dexmethylphenidate: A Synthesis of Findings from 3 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of serdexmethylphenidate and dexmethylphenidate: A Synthesis of Findings from 3 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Main Research Findings

Serdexmethylphenidate/dexmethylphenidate (SDX/d-MPH) is a medication approved for the treatment of attention-deficit/hyperactivity disorder (ADHD) in patients aged 6 years and older. 2 A 12-month open-label safety study of SDX/d-MPH in children with ADHD found that SDX/d-MPH was well tolerated and comparable to other methylphenidate products. 2 A post hoc analysis of this 12-month study examined the impact of SDX/d-MPH on growth in children with ADHD over 12 months. 2 The study found that SDX/d-MPH resulted in modest reductions in expected weight and lower-than-expected increases in height; however, these changes were not considered clinically significant. 2 Additionally, sleep behavior was assessed in children with ADHD who were receiving SDX/d-MPH treatment. 1 A separate randomized, double-blind, dose-optimized laboratory classroom study compared the efficacy and safety of SDX/d-MPH to placebo in children with ADHD. 3 SDX/d-MPH demonstrated significant improvement in ADHD symptoms compared to placebo, with a rapid onset and extended duration of effect. 3 The medication was found to be safe, with adverse events comparable to those observed with other stimulant treatments. 3 」

Benefits and Risks

Benefits Summary

SDX/d-MPH has shown promise in improving ADHD symptoms in children. 3 It has also been demonstrated to be safe, with a comparable safety profile to other stimulant treatments for ADHD. 3 」

Risks Summary

SDX/d-MPH may potentially contribute to slight reductions in weight and height growth. 2 There is also a possibility of sleep-related side effects. 1 」

Comparison Across Studies

Similarities Across Studies

All three studies focused on evaluating the effects of SDX/d-MPH in children with ADHD. 2 1 3 」

Differences Across Studies

The three studies employed distinct objectives and research designs. 2 1 3 2 specifically evaluated the impact of SDX/d-MPH on growth in children with ADHD. 1 assessed the impact of SDX/d-MPH on sleep behavior in children with ADHD. 3 compared the efficacy and safety of SDX/d-MPH to placebo in children with ADHD. 3 」

Consistency and Contradictions in Results

The results of the three studies generally suggest that SDX/d-MPH is effective in improving ADHD symptoms in children and possesses a favorable safety profile. 2 1 3 However, there are contradictions concerning the potential impact of SDX/d-MPH on growth and sleep behavior. 2 1 」

Implications for Real-World Applications

While SDX/d-MPH holds promise for improving ADHD symptoms, it's essential to be aware of its potential effects on growth and sleep. 2 1 The use of SDX/d-MPH should be under the guidance of a healthcare professional. 2 1 3 」

Limitations of Current Research

The three studies were relatively small in scale and lacked long-term follow-up assessments. 2 1 3 Further research is necessary to comprehensively evaluate the long-term effects of SDX/d-MPH on growth and sleep behavior. 2 1 」

Future Research Directions

Longitudinal studies are warranted to evaluate the long-term impacts of SDX/d-MPH on growth and sleep behavior. 2 1 Research is also needed to determine the optimal dosage and treatment duration for SDX/d-MPH. 2 1 3 」

Conclusion

SDX/d-MPH shows promise in managing ADHD symptoms in children, but potential effects on growth and sleep should be considered. 2 1 It's crucial to use SDX/d-MPH under the guidance of a healthcare professional. 2 1 3 Further research is anticipated to provide a more comprehensive understanding of the safety and efficacy of SDX/d-MPH. 2 1 3 」

Literature analysis of 3 papers
Positive Content
2
Neutral Content
1
Negative Content
0
Article Type
1
0
0
0
3
2.

Analysis of Growth Velocity in Children with Attention-Deficit/Hyperactivity Disorder Treated for up to 12 Months with Serdexmethylphenidate/Dexmethylphenidate.

Author: ChildressAnn C, CutlerAndrew J, PatelMaitrey, OhCharles

Minimal growth impact
Well-tolerated
Lower height increase
Modest weight reduction

Serdexmethylphenidate/dexmethylphenidate (SDX/d-MPH) is a medication used to treat attention-deficit/hyperactivity disorder (ADHD). This post-hoc analysis of a 12-month safety study found that long-term treatment with SDX/d-MPH was associated with modest reductions in expected weight and lower-than-expected increases in height.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

3.

A Randomized, Controlled Laboratory Classroom Study of Serdexmethylphenidate and d-Methylphenidate Capsules in Children with Attention-Deficit/Hyperactivity Disorder.

Author: KollinsScott H, BraeckmanRene, GuentherSven, BarrettAndrew C, MickleTravis C, OhCharles, MarraffinoAndrea, CutlerAndrew J, BramsMatthew N

ADHD treatment
Decreased appetite
Insomnia

Once-daily serdexmethylphenidate/dexmethylphenidate (SDX/d-MPH) capsules were found to significantly improve ADHD symptoms in children aged 6-12 compared to placebo, with a rapid onset and extended duration of treatment effect. The treatment was safe, with adverse events comparable to other stimulant treatments.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.